US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025

April 2019 | 700 pages | ID: UDFEA0EEDF0EN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025' Report Highlights:

• US Breast Cancer Drug Market Opportunity: US$ 20 Billion
• US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
• US Breast Cancer Marketed Drugs: 42 Drugs
• US Breast Cancer Drug Clinical Pipeline: 317 Drugs
• Dosage & Pricing Insight for Preventive & Treatment Drugs
• US Breast Cancer Drug Market Dynamics

Breast cancer is the most commonly diagnosed cancer in American women. Breast cancer occurring in a woman under 40 is not a typical condition anymore. Changing lifestyle with numerous other factors like early menarche, late age at first childbirth, late menopause and prolonged exposure to endogenous oestrogens are surging the breast cancer drug market at a high rate. Also, short breast-feeding timeframe, rising of obesity in women after menopause, increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills which causes increased levels of oestrogen are boosting the breast cancer drug market to its peak.

Various breast cancer therapeutics have come into existence like hormone drugs, chemotherapy drugs and targeted drugs. With advancements in drug delivery systems target specific therapies are prevailing. Also ER positive drugs for breast cancer are being introduced to the market. Drugs approved for prevention of breast cancer like Raloxifene Hydrochloride, Elvista etc. and drugs approved for the treatment of breast cancer like Abemaciclib, Abraxane, Xeloda, Taxol, Methotrexate etc. have been mentioned in detail with indication, dosing and pricing in our report on US Breast Cancer Drug Market.

US breast cancer drug market has high potency of growth with 42 drugs being commercially available and more than 300 of them being in the clinical pipeline. It is definitive that the market will grow due to the increase in prevalence of breast cancer and large group of geriatric population. Also, it has become a priority for researches and everyone linked to the healthcare system to find a cure for the second most commonly occurring disease. Even if the growth is slow it will increase exponentially in the near future.

Inaccessibility of the absolute treatment has given a wide scope of stage for the improvement of the US breast cancer drug market. Pharmaceutical companies are now concentrating on the improvement of new products which will be cost effective and will also have least side effects. Different organizations are also engaged with the advancement of specific types of molecules and novel therapies. These organizations have adapted the methodologies of the acquisitions, and furthermore propelling of the new products so as to endeavor in this huge and competitive market. Additionally, competition among new market players is likewise expected to expedite the growth for breast cancer drugs market in near future.

Contents

1. US - CANCER INCIDENCE & PREVALENCE

2. US BREAST CANCER MARKET LANDSCAPE

2.1 Incidence & Prevalence
2.2 Diagnosis of Breast Cancer

3. US BREAST CANCER DRUG MARKET

3.1 Overview US Breast Cancer Drug Market
3.2 Diagnosis & Screening Market Scenario
3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. FORWARD LOOKING DEVELOPMENTS IN BREAST CANCER DRUG MARKET

4.1 ER Positive Breast Cancer
  4.1.1 CDK4/6 Inhibitors
  4.1.2 PI3K Inhibitors
  4.1.3 Crizotinib for Lobular Breast Cancer
4.2 HER2-Positive Breast Cancer
  4.2.1 Palbociclib & Herceptin (Spain)
  4.2.2 Tecentriq – FDA Approval for Breast Cancer
4.3 Triple Negative Breast Cancer
  4.3.1 Atezolizumab & Nab-Paclitaxel
  4.3.2 Sacituzumab Govitecan
  4.3.3 Carboplatin & Docetaxel

5. US – DOSAGE & PRICING INSIGHT FOR DRUGS APPROVED FOR THE PREVENTION OF BREAST CANCER

5.1 Raloxifene Hydrochloride
5.2 Elvista
5.3 Tamoxifen Citrate

6. US - DOSAGE & PRICING INSIGHT FOR DRUGS APPROVED FOR THE TREATMENT OF BREAST CANCER

6.1 Abemaciclib
6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
6.3 Ado-Trastuzumab Emtansine
6.4 Afinitor (Everolimus)
6.5 Anastrozole
6.6 Aromasin (Exemestane)
6.7 Xeloda (Capecitabine)
6.8 Docetaxel (Docetaxel Anhydrous)
6.9 Doxorubicin Hydrochloride
6.10 Ellence (Epirubicin Hydrochloride)
6.11 Fluorouracil
6.12 Taxol (Paclitaxel)
6.13 Methotrexate
6.14 Cyclophosphamide

7. US BREAST CANCER DRUG MARKET DYNAMICS

7.1 Market Drivers
  7.1.1 Increasing Incidence of Breast Cancer
  7.1.2 Research & Development for Novel Drugs
  7.1.3 Increase in Healthcare Expenditure & Funding
  7.1.4 Increasing Breast Cancer Screening Programs
  7.1.5 Rising Consumption of Tobacco & Alcohol
7.2 US Breast Cancer Drug Market Challenges
  7.2.1 Pricing Pressure Experienced by the Innovators
  7.2.2 High Cost associated with Drug Development & Clinical Trials
  7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - BREAST CANCER DRUG MARKET FORECAST

8.1 Future Potential of US Breast Cancer Drug Market
8.2 Opportunities for Forthcoming Drug Classes

9. US - BREAST CANCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE

9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
9.10 Registered

10. US - MARKETED BREAST CANCER DRUG CLINICAL INSIGHT BY COMPANY

10.1 Afinitor
10.2 LYNPARZA
10.3 Abraxane
10.4 Verzenio
10.5 Kisqali
10.6 Lymphoseek
10.7 Kadcyla
10.8 Ibrance
10.9 Nerlynx
10.10 Soltamox
10.11 Tykerb
10.12 Zoladex
10.13 Omnitarg, Perjeta
10.14 Halaven
10.15 Taxotere
10.16 Other( 27 Drugs Profiles)

11. COMPETITIVE LANDSCAPE

11.1 Agilent Technologies
11.2 AstraZeneca
11.3 Bayer HealthCare Pharmaceuticals
11.4 Bristol-Myers Squibb
11.5 Eisai Co Ltd
11.6 Eli Lilly
11.7 Novartis
11.8 Onyx Pharmaceuticals
11.9 Orion
11.10 Perrigo
11.11 Pfizer
11.12 Roche

List Of Figures

LIST OF FIGURES

Figure 1-1: US – Estimated New Cancer Cases & Death (Number), 2019
Figure 1-2: US – Estimated New Cancer Cases & Death (Number), 2018
Figure 1-3: US – Estimated New Cancer Cases & Death in Women, (Number), 2019
Figure 1-4: US – Estimated New Cancer Cases & Death in Men (Number), 2019
Figure 1-5: US – Estimated New Cancer Cases & Death in Women (Number), 2018
Figure 1-6: US – Estimated New Cancer Cases & Death in Men (Number), 2018
Figure 1-7: US – Estimated New Cancer Cases in Men by Type (Number), 2019
Figure 1-8: US – Estimated New Cancer Cases in Men by Type (Number), 2018
Figure 1-9: US – Cancer Death Cases in Men by Type (Number), 2019
Figure 1-10: US – Cancer Death Cases in Men by Type (Number), 2018
Figure 1-11: US – Estimated New Cancer Cases in Women by Type (Number), 2019
Figure 1-12: US – Estimated New Cancer Cases in Women by Type (Number), 2018
Figure 1-13: US – Women Death by Cancer Type (Number), 2019
Figure 1-14: US – Women Death by Cancer Type (Number), 2018
Figure 2-1: US – Breast Cancer Cases in Women (Number), 2019
Figure 2-2: US – Invasive Breast Cancer Cases in Women & Men (Number), 2019
Figure 2-3: US – Risk of Developing Breast Cancer in Women by BRCA Genes (%), April’ 2019
Figure 2-4: US – Risk of Developing Breast Cancer in Women & Men by BRCA2 (%), April’ 2019
Figure 2-5: US – Genetic & Epigenetic Breast Cancer Prevalence in Women (%), April’ 2019
Figure 2-6: US – Estimated New Breast Cancer Cases & Death (Number), 2019
Figure 2-7: US – Estimated New Breast Cancer Cases & Death in Women (Number), 2019
Figure 2-8: US – Estimated New Breast Cancer Cases & Death in Men, (Number), 2019
Figure 2-9: Global – Breast Cancer Occurance due to Genetic Abnormalities (Parents & Aging)
Figure 2-10: Procedures for Diagnosis of Breast Cancer
Figure 3-1: Different Screening Tests available for Breast Cancer
Figure 3-2: US Breast Cancer Clinical Pipeline By Phase (%), 2019 till 2025
Figure 3-3: US Breast Cancer Clinical Pipeline By Phase (Number), 2019 till 2025
Figure 3-4: US - Breast Cancer Clinical Pipeline By Mechanism of Action (%), 2019 till 2025
Figure 3-5: US - Breast Cancer Clinical Pipeline By Drug Class (%), 2019 till 2025
Figure 3-6: US - Breast Cancer Clinical Pipeline By Company (%), 2019 till 2025
Figure 3-7: US - Breast Cancer Clinical Pipeline By Patient Segment (%), 2019 till 2025
Figure 4-1: Ongoing Different Research Areas of Breast Cancer
Figure 5-1: Raloxifene Hydrochloride – Dosage for Osteoporosis & Breast Cancer, One Tablet Daily (Milligram)
Figure 5-2: Raloxifene Hydrochloride – Price per Tablet by Pack Size (US$/Tablet), April’ 2019
Figure 5-3: Raloxifene Hydrochloride – Price per Pack Size (US$/Pack) April’ 2019
Figure 5-4: Elvista – Dosage for Osteoporosis & Breast Cancer, One Tablet Daily (Milligram)
Figure 5-5: Elvista – Price per Tablet by Pack Size (US$/Tablet), April’ 2019
Figure 5-6: Elvista – Price per Pack by Size (US$/Pack), April’ 2019
Figure 5-7: Tamoxifen citrate – Price per Tablet by Pack Size for 10 Milligram Dose (US$/Tablet), April’ 2019
Figure 5-8: Tamoxifen citrate – Cost of Different Quantities for 10 Milligram Dose (US$/Pack), April’ 2019
Figure 5-9: Tamoxifen citrate – Cost of Different Quantities for 20 Milligram Dose (US$/Tablet), April’ 2019
Figure 5-10: Tamoxifen citrate – Cost of Different Quantities for 20 Milligram Dose (US$/Pack), April’ 2019
Figure 6-1: Verzenio (Abemaciclib) – Recommended Dosage (Combination Therapy vs Monotherapy) in Milligrams
Figure 6 2: Verzenio – Cost (US$)per Tablet across various Doses (Milligram), April’2019
Figure 6-3: Abraxene – Dosage via Intravenously (Milligram) & Cost for 1 powder of Injection (Milligram), (US$), April’ 2019
Figure 6-4: Kadcyla (Ado-Trastuzumab Emtansine) – Cost per Unit (Milligram) of 1 powder (US$/Injection), April’ 2019
Figure 6-5: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Tablet), April’ 2019
Figure 6-6: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Pack), April’ 2019
Figure 6-7: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Tablet), April’ 2019
Figure 6-8: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Pack), April’ 2019
Figure 6-9: Exemestane: Cost as per Quantity for 25 Milligram Dose Per Tablet vs Pack, (US$), April’ 2019
Figure 6-10: Xeloda (Capecitabine) – Dosage as per Oral Intake (Milligram per Metre Square)
Figure 6-11: Xeloda - Cost of Different Quantities for 150 & 500 Milligram Dose (US$/Unit), April’ 2019
Figure 6-12: Xeloda - Cost of Different Quantities for 150 & 500 Milligram Dose (US$/Pack), April’ 2019
Figure 6-13: Docetaxel (Docetaxel Anhydrous) – Minimum & Maximum Dosage for Metaststic Breast Cancer (Milligram per Metre Square)
Figure 6-14: Docetaxel (Docetaxel Anhydrous) –Dosage for Node-Positive Breast Cancer (Milligram per Metre Square), Administered with Doxorubicin & Cyclophosphamide
Figure 6-15: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-16: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-17: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-18: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-19: Doxorubicin Hydrochloride – Price per Unit for Different Quantities of 2 Milligram per Millilitre Dose (US$), April’ 2019
Figure 6-20: Doxorubicin Hydrochloride – Price per Pack for Different Quantities of 2 Milligram per Millilitre Dose (US$), April’ 2019
Figure 6-21: Epirubicin - Price per Unit for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-22: Epirubicin - Price per Pack for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-23: Fluorouracil - Price per Unit for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-24: Fluorouracil - Price per Pack for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-25: Paclitaxel – Recommended v/s Adjusted Dosage (Milligram per Metre Square) intravenously
Figure 6-26: Taxol (Paclitaxel) - Price per Unit for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-27: Taxol (Paclitaxel) - Price per Pack for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April’ 2019
Figure 6-28: Methotrexate - Price per Unit for Injectable Powder (Gram) & Injectable Solution (Milligram per Millilitre) for Injection (US$), April’ 2019
Figure 6-29: Methotrexate - Price per Tablet for Supply of 2.5 Milligram Dose (US$), April’ 2019
Figure 6-30: Methotrexate - Price per Pack for Supply of 2.5 Milligram Dose (US$), April’ 2019
Figure 6-31: Cyclophosphamide - Price per Unit for Supply of 1 Gram, 2 Gram & 5Milligram Dose for 1 Powder of Injection (US$), April’ 2019
Figure 6-32: Cyclophosphamide - Price per Capsule for Supply of 25 & 50 Milligram Dose (US$), April’ 2019
Figure 6-33: Cyclophosphamide - Price per Pack (100) for Supply of 25 & 50 Milligram Dose (US$), April’ 2019
Figure 7-1: Drivers of Breast Cancer Drug Market
Figure 7-2: US – Estimation of Newly Diagnosed Cancers in Women, April’ 2019
Figure 7-3: Challenges of Breast Cancer Drug Market
Figure 8-1: US - Breast Cancer Drug Market Opportunity (US$ Billion), 2019 - 2025

List Of Tables

LIST OF TABLES

Table 6-1: Verzenio Dosage Modification for Adverse Reactions
Table 6-2: Regimens for Ellence (Epirubicin Hydrochloride Injection)